Geneva, Oct. 8 -- International Clinical Trials Registry received information related to the study (NCT07193563) titled 'ENX-102 Phase 2 Social Anxiety Disorder' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Engrail Therapeutics INC

Condition: Social Anxiety Disorder (SAD)

Intervention: Drug: ENX-102

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: September 5, 2025

Target Sample Size: 220

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07193563

Published by HT Digital Co...